KeyBanc reiterates Encompass Health stock rating on benign Medicare proposal

Encompass Health reported Q4 2025 EPS of $1.46 vs $1.30 consensus, revenue $1.54B in line, and adjusted EBITDA $336.0M vs $313.2M consensus. CMS proposed a 2.4% Medicare payment increase to inpatient rehabilitation facilities for FY2027, which KeyBanc called roughly in line with expectations and reiterated an Overweight rating and $145 price target. Shares trade at $97.39 (near a 52-week low of $92.77) and InvestingPro flags a PEG of 0.71, suggesting the stock may be undervalued and could see H2 outperformance if policy/headline overhang fades.

Analysis

The CMS signal reduces a near-term policy overhang for inpatient rehab operators, which should de-risk consensus volume/margin assumptions over the next 6–12 months. The more important second-order effect is on staffing economics: marginal reimbursement lifts mainly flow to operating leverage if therapy and nursing wage inflation normalizes, otherwise labor pass-throughs will mute the EPS upside. Expect facility utilization and case-mix management to be the operational levers that determine which operators capture the revenue tailwind and which see it eroded by cost pressure.

Competitive dynamics favor operators with higher fixed-cost leverage and diversified referral channels (integrated hospital partners, managed-care contracts) because a modest reimbursement uptick compounds through occupancy and margin. Conversely, providers concentrated in low-acuity referral markets or with outsized contract exposure to Medicaid/home-health substitution are most exposed if payers accelerate site-neutral policy or steer patients to lower-cost settings. Equipment and outsourced therapy vendors could see order volatility: a sustained revenue lift will drive capex/service demand, while a policy reversal will quickly curtail it.

Key catalysts and risk paths are distinct in timing: the final FY27 rule and subsequent CMS guidance are 3–9 month binary catalysts, while labor markets and case-mix trends play out continuously over the next 1–3 years. A 100–200 bps swing in net reimbursement or a persistent 100–200 bps increase in labor costs would move adjusted EBITDA by low-to-mid single-digit percentage points — enough to flip consensus beats into misses. Monitor same-store discharge growth, payer mix shifts, and CMS audit/coverage changes as high-frequency signals.

Valuation and positioning should treat this as an event-driven, operational stock rather than a pure policy play. If management can sustain volume and control labor inflation, the stock should re-rate versus peers; if not, downside is concentrated and fast. Use structured exposure that pays off into the post-rule information set while protecting against policy or labor shocks.

Key Decisions for Investors

• Core long EHC (6–12 months): establish a 3–5% portfolio position size with a protective hedge (buy 9–12 month puts ~10–15% OTM or a collar). Rationale: asymmetric upside from clearer Medicare pricing tailwind vs limited near-term downside if you cap risk via options; target relative TSR outperformance of 15–30% if operational execution holds.
• Pairs trade (6–12 months): long EHC / short SEM (Select Medical) equal notional. Rationale: overweight operators with cleaner case mix and diversified referral sources; expect 4–8% relative outperformance for EHC if reimbursement flow-through and occupancy improve while SEM, with different exposure, lags.
• Defined-risk options (3–9 months): buy a directional call spread on EHC (long 9–12 month ITM or near-ATM call, sell higher strike call) sized for 1–2% portfolio risk. Rationale: levered exposure into the final FY27 rule and subsequent earnings with capped premium outlay; payoff >3x if catalysts are positive.
• Event short hedge (9–18 months): establish a small short/underweight position in names concentrated in low-acuity post-acute care or exposed to site-neutral moves (examples: providers with heavier SNF/home-health overlap). Rationale: protects portfolio from a policy pivot toward site-neutral payments that would compress IRF pricing and drive patient migration.